|
1
|
Holliday R: The inheritance of epigenetic
defects. Science. 238:163–170. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Das OP and Messing J: Variegated phenotype
and developmental methylation changes of a maize allele originating
from epimutation. Genetics. 136:1121–1141. 1994.PubMed/NCBI
|
|
3
|
Schofield PN, Joyce JA, Lam WK, Grandjean
V, Ferguson-Smith A, Reik W and Maher ER: Genomic imprinting and
cancer; new paradigms in the genetics of neoplasia. Toxicol Lett.
120:151–160. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hitchins M, Williams R, Cheong K, et al:
MLH1 germline epimutations as a factor in hereditary nonpolyposis
colorectal cancer. Gastroenterology. 129:1392–1399. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hitchins MP, Wong JJ, Suthers G, Suter CM,
Martin DI, Hawkins NJ and Ward RL: Inheritance of a
cancer-associated MLH1 germ-line epimutation. N Engl J Med.
356:697–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Valle L, Carbonell P, Fernandez V, Dotor
AM, Sanz M, Benitez J and Urioste M: MLH1 germline epimutations in
selected patients with early-onset non-polyposis colorectal cancer.
Clin Genet. 71:232–237. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morak M, Schackert HK, Rahner N, et al:
Further evidence for heritability of an epimutation in one of 12
cases with MLH1 promoter methylation in blood cells clinically
displaying HNPCC. Eur J Hum Genet. 16:804–811. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hitchins MP and Ward RL: Erasure of MLH1
methylation in spermatozoa-implications for epigenetic inheritance.
Nat Genet. 39:12892007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cooper WN, Luharia A, Evans GA, et al:
Molecular subtypes and phenotypic expression of Beckwith-Wiedemann
syndrome. Eur J Hum Genet. 13:1025–1032. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schönherr N, Meyer E, Roos A, Schmidt A,
Wollmann HA and Eggermann T: The centromeric 11p15 imprinting
centre is also involved in Silver-Russell syndrome. J Med Genet.
44:59–63. 2007.PubMed/NCBI
|
|
11
|
Conrad DF, Pinto D, Redon R, et al:
Origins and functional impact of copy number variation in the human
genome. Nature. 464:704–712. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tufarelli C, Stanley JA, Garrick D, Sharpe
JA, Ayyub H, Wood WG and Higgs DR: Transcription of antisense RNA
leading to gene silencing and methylation as a novel cause of human
genetic disease. Nat Genet. 34:157–165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Friend SH, Bernards R, Rogelj S, Weinberg
RA, Rapaport JM, Albert DM and Dryja TP: A human DNA segment with
properties of the gene that predisposes to retinoblastoma and
osteosarcoma. Nature. 323:643–646. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishisho I, Nakamura Y, Miyoshi Y, et al:
Mutations of chromosome 5q21 genes in FAP and colorectal cancer
patients. Science. 253:665–669. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hussussian CJ, Struewing JP, Goldstein AM,
et al: Germline p16 mutations in familial melanoma. Nat Genet.
8:15–21. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Greger V, Passarge E, Höpping W, Messmer E
and Horsthemke B: Epigenetic changes may contribute to the
formation and spontaneous regression of retinoblastoma. Hum Genet.
83:155–158. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakai T, Toguchida J, Ohtani N, Yandell
DW, Rapaport JM and Dryja TP: Allele-specific hypermethylation of
the retinoblastoma tumor-suppressor gene. Am J Hum Genet.
48:880–888. 1991.PubMed/NCBI
|
|
18
|
Herman JG, Latif F, Weng Y, et al:
Silencing of the VHL tumor-suppressor gene by DNA methylation in
renal carcinoma. Proc Natl Acad Sci USA. 91:9700–9704. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kane MF, Loda M, Gaida GM, Lipman J,
Mishra R, Goldman H, Jessup JM and Kolodner R: Methylation of the
hMLH1 promoter correlates with lack of expression of hMLH1 in
sporadic colon tumors and mismatch repair-defective human tumor
cell lines. Cancer Res. 57:808–811. 1997.PubMed/NCBI
|
|
20
|
Dobrovic A and Simpfendorfer D:
Methylation of the BRCA1 gene in sporadic breast cancer. Cancer
Res. 57:3347–3350. 1997.PubMed/NCBI
|
|
21
|
de la Chapelle A: Genetic predisposition
to human disease: allele-specific expression and low-penetrance
regulatory loci. Oncogene. 28:3345–3348. 2009.PubMed/NCBI
|
|
22
|
Weisenberger DJ, Siegmund KD, Campan M, et
al: CpG island methylator phenotype underlies sporadic
microsatellite instability and is tightly associated with BRAF
mutation in colorectal cancer. Nat Genet. 38:787–793. 2006.
View Article : Google Scholar
|
|
23
|
Gazzoli I, Loda M, Garber J, Syngal S and
Kolodner RD: A hereditary nonpolyposis colorectal carcinoma case
associated with hypermethylation of the MLH1 gene in normal tissue
and loss of heterozygosity of the unmethylated allele in the
resulting microsatellite instability-high tumor. Cancer Res.
62:3925–3928. 2002.
|
|
24
|
Suter CM, Martin DI and Ward RL: Germline
epimutation of MLH1 in individuals with multiple cancers. Nat
Genet. 36:497–501. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miyakura Y, Sugano K, Konishi F, et al:
Extensive methylation of hMLH1 promoter region predominates in
proximal colon cancer with microsatellite instability.
Gastroenterology. 121:1300–1309. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miyakura Y, Sugano K, Konishi F, et al:
Methylation profile of the MLH1 promoter region and their
relationship to colorectal carcinogenesis. Genes Chromosomes
Cancer. 36:17–25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miyakura Y, Sugano K, Akasu T, et al:
Extensive but hemiallelic methylation of the hMLH1 promoter region
in early-onset sporadic colon cancers with microsatellite
instability. Clin Gastroenterol Hepatol. 2:147–156. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chan TL, Yuen ST, Kong CK, et al:
Heritable germline epimutation of MSH2 in a family with hereditary
nonpolyposis colorectal cancer. Nat Genet. 38:1178–1183. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Raval A, Tanner SM, Byrd JC, et al:
Downregulation of death-associated protein kinase 1 (DAPK1) in
chronic lymphocytic leukemia. Cell. 129:879–890. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reddy AN, Jiang WW, Kim M, Benoit N,
Taylor R, Clinger J, Sidransky D and Califano JA: Death-associated
protein kinase promoter hypermethylation in normal human
lymphocytes. Cancer Res. 63:7694–7698. 2003.PubMed/NCBI
|
|
31
|
Armes JE and Venter DJ: The pathology of
inherited breast cancer. Pathology. 34:309–314. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lakhani SR, Van De Vijver MJ, Jacquemier
J, Anderson TJ, Osin PP, MaGuffog L and Easton DF: The pathology of
familial breast cancer: predictive value of immunohistochemical
markers estrogen receptor, progesterone receptor, HER-2, and p53 in
patients with mutations in BRCA1 and BRCA2. J Clin Oncol.
20:2310–2318. 2002. View Article : Google Scholar
|
|
33
|
Foulkes WD, Stefansson IM, Chappuis PO,
Bégin LR, Goffin JR, Wong N, Trudel M and Akslen LA: Germline BRCA1
mutations and a basal epithelial phenotype in breast cancer. J Natl
Cancer Inst. 95:1482–1485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Esteller M, Silva JM, Dominguez G, et al:
Promoter hypermethylation and BRCA1 inactivation in sporadic breast
and ovarian tumors. J Natl Cancer Inst. 92:564–569. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Catteau A and Morris JR: BRCA1
methylation: a significant role in tumour development? Semin Cancer
Biol. 12:359–371. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hedenfalk I, Duggan D, Chen Y, et al:
Gene-expression profiles in hereditary breast cancer. N Engl J Med.
344:539–548. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Snell C, Krypuy M, Wong EM; kConFab
investigators; Loughrey MB and Dobrovic A: BRCA1 promoter
methylation in peripheral blood DNA of mutation negative familial
breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer
Res. 10:R122008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hampel H, Frankel WL, Martin E, et al:
Feasibility of screening for Lynch syndrome among patients with
colorectal cancer. J Clin Oncol. 26:5783–5788. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Peltomäki P and Vasen H: Mutations
associated with HNPCC predisposition - Update of ICG-HNPCC/INSiGHT
mutation database. Dis Markers. 20:269–276. 2004.PubMed/NCBI
|
|
40
|
Hirata K, Kanemitsu S, Nakayama Y, Nagata
N, Itoh H, Ohnishi H, Ishikawa H and Furukawa Y; HNPCC registry and
genetic testing project of the Japanese Society for Cancer of the
Colon and Rectum (JSCCR): A novel germline mutation of MSH2 in a
hereditary nonpolyposis colorectal cancer patient with liposarcoma.
Am J Gastroenterol. 101:193–196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Naruse H, Ikawa N, Yamaguchi K, et al:
Determination of splice-site mutations in Lynch syndrome
(hereditary nonpolyposis colorectal cancer) patients using
functional splicing assay. Fam Cancer. 8:509–517. 2009. View Article : Google Scholar
|
|
42
|
Winter MJ, Nagtegaal ID, van Krieken JH
and Litvinov SV: The epithelial cell adhesion molecule (Ep-CAM) as
a morpho-regulatory molecule is a tool in surgical pathology. Am J
Pathol. 163:2139–2148. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ligtenberg MJ, Kuiper RP, Chan TL, et al:
Heritable somatic methylation and inactivation of MSH2 in families
with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat
Genet. 41:112–117. 2009.PubMed/NCBI
|
|
44
|
Fraga MF, Ballestar E, Paz MF, et al:
Epigenetic differences arise during the lifetime of monozygotic
twins. Proc Natl Acad Sci USA. 102:10604–10609. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Issa JP, Ottaviano YL, Celano P, Hamilton
SR, Davidson NE and Baylin SB: Methylation of the oestrogen
receptor CpG island links ageing and neoplasia in human colon. Nat
Genet. 7:536–540. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rose MG: Hematology: azacitidine improves
survival in myelodysplastic syndromes. Nat Rev Clin Oncol.
6:502–503. 2009. View Article : Google Scholar : PubMed/NCBI
|
